WuXi PharmaTech (NYSE:WX) exceeded its earnings estimates for both revenue and earnings for Q2 2014. Revenue increased 14.8% to $163.4 million, beating estimates by $1.29 million. EPS increased 5.2% to $0.49, beating estimates by over 4%. The revenue growth was driven by small-molecule manufacturing and biologics. Segment revenue growth for Manufacturing Services, China Lab Services, and U.S. Lab Services, increased 19.3%, 14.2%, and 9.6% respectively. This performance reinforces my positive outlook for the company.
WuXi also raised its revenue and earnings guidance for 2014. The company now expects revenue to be between $665 million - $670 million, up from previous estimates of $660 million - $670 million. Non-GAAP diluted EPS is expected to be $1.82 - $1.86, up from previous guidance of $1.80 - $1.85. This increase in guidance is likely to provide a catalyst for the stock until the current quarter's earnings are reported.
I pointed out in my previous article on the company that WuXi's stock was likely to increase on its earnings upgrades in 2013 and as the company grows earnings at an above average rate. The stock is up about 50% from the time that article was written. The company is upgrading its earnings guidance again for 2014, so I would expect more strong increases in the stock price if these estimates are met. WuXi's subsidiary Shanghai SynTheAll Pharmaceutical Company just passed FDA inspection in July to manufacturer the active pharmaceutical ingredient (API) for a branded commercial drug. The company's strong performance and continual investments for sustaining growth are likely to catalyze the stock going forward.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.